Documente Academic
Documente Profesional
Documente Cultură
PHARMACEUTICAL INDUSTRY IN
PAKISTAN
NASIR JAVAID CHOWDHRY
SEPTEMDBER 2014
:
:
COUNTRIES
MARKET SHARE
US
31%
CAGR
(2013 17)
1 4%
EU 5
13%
(-1%) 2%
JAPAN
CHINA
BRIC
TIER 3
9%
15%
8%
10%
13 16%
10 13%
6 9%
CAGR
(2008 12)
Germany,
Finance, Italy,
Spain, UK
22%
16%
Source: IMS
CONTENTS
1. Global Pharmaceutical Industry and Trends (A
Synopsis)
2. Importance of the Pak Pharma Sector
3. MFN Status Threat or Opportunity?
4. Evolution of Pharma in India vs. Pakistan:
- Regulatory Environment
- Infrastructure
5. Likely Outcomes if MFN Granted Today
6. Possible Solutions
Direct
1.
2.
3.
4.
5.
6.
7.
8.
Self Reliance
Foreign exchange Saving
Employment generation
Employment for Females
Skill Upgradation
FDI
Transfer of Tech. & Know How
Critical Support in Man Made
& National disasters
1.
2.
3.
4.
5.
Indirect employment
Investment
Skill Acquisition
Technology spillovers
BRAIN DRAIN REVERSAL
1. indignous growth
2. Productive Diversification
3. Human development
4. Revenue generation for govt.
Description
Total Pharma Market
Growth Rate
Intl. Ranking Value Wise
Manufacturing Plants
Pakistan
USD 2 Bn
15%
45
>700
None
India
USD 14 Bn
16%
15
25,000
>150
Pharmaceutical Exports
>USD 190mi
>USD
20,000mi
Negligible
70%
Pharmaceutical Machinery
Manufacturing
20-25%
90%
1979:
1995:
2002:
1976:
Drugs Act 1976 Passed, allowing for use of Brand Names, but
continuing with Draconian Price Controls pn 100% of all
Pharmaceutical Products.
2001:
2011:
Result:
Stifled Industry Growth
Depressed Profitability
Discouraged Investment
Restricted Scale of Industry to Uncompetitive Levels
INDIAN MRP
IN PKR
Difference
AUGMENTIN
91.68
259.27
65%
GLUCOPHAGE
69.14
397.70
83%
3
4
5
PONSTAN
AMPICLOX
INTERFERON
203.31
149.55
450.00
336.47
235.07
1,578.31
40%
36%
71%
ERYTHROCIN
200.86
313.30
36%
HUMULIN70/30
406.54
578.01
30%
8
9
10
11
12
13
14
15
PANADOL
MOTILIUM
CALPOL
TARIVID
DIAMICRON
LINCOCIN
CECLOR
KLARICID
31.04
125.38
26.31
304.31
128.78
114.12
205.58
648.53
41.12
175.68
35.54
382.69
150.83
140.88
227.97
703.13
25%
29%
26%
20%
15%
19%
10%
8%
16
HAEMACCEL
275.48
279.64
1%
NAME
India
Pakistan
Price Control
Nominal
100%
2 weeks
Indefinite
Provided at Base
Tariffs (free of GST, IT
and other taxes (in
SEZs)
Intermittent
Availability. Lowest
priority
5-25%
Utilities
Description
Pakistan
Bangladesh
USD 2.3 Bn
15%
45
700
USD 1.5 Bn
12%
58
210
Negligible
15%
20-25%
15%
CASE STUDY:
BRAZIL
Recommendation I:
Recommendation II:
Amend Drug Registration Policy of the DRAP to allow registration of only
those imported brands that are manufactured in plants approved by and
registered and sold freely in USA, UK, EU Countries, Switzerland, Japan or
Australia.
Simultaneously, Liberalize the Regulatory Environment for Pakistani
Companies and improve regulatory standards to match international
GMP Requirements.
By 2020